HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.
Lijuan Hu, Xudong Wei, Weili Zhao...
https://pubmed.ncbi.nlm.nih.gov/39892383/Actively Recruiting
Led by Hutchmed · Updated on 2025-08-14
316
Participants Needed
53
Research Sites
39 weeks
Total Duration
Researchers are evaluating the drug HMPL-306 compared to salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia AML who have mutations in the IDH1 or IDH2 genes. This phase III, multicenter, open-label study divides patients into two groups based on their specific IDH mutation and investigates the effectiveness, safety, and pharmacokinetics of HMPL-306. The trial aims to provide new treatment options for AML patients with these genetic mutations who have not responded to prior therapies. Patients are randomly assigned to receive either HMPL-306 monotherapy or one of several salvage chemotherapy regimens selected by their investigator. HMPL-306 is given orally at 250 mg once daily for the first 28-day cycle, then 150 mg once daily for subsequent cycles. Salvage chemotherapy options include intensive regimens like EAMitox and FLAGIda, or less intensive treatments like azacitidine and LoDAC. Treatment continues in 28-day cycles until treatment failure or other study-defined endpoints. Participants will undergo genetic testing to confirm IDH mutation status before enrollment and will be closely monitored throughout the study. This includes bone marrow biopsies, quality of life assessments, and evaluations of treatment response and safety using established criteria. Follow-up extends beyond treatment discontinuation, including safety monitoring and long-term tracking of survival and disease progression. The total study duration may last up to approximately 33 months depending on individual patient outcomes and study progress.
CONDITIONS
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
E
Erin Lou, Doctor
Y
Yu Wang, Bachelor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hutchmed
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Until treatment failure or discontinuation, with repeated 28-day cycles
Participants receive treatment with either HMPL-306 monotherapy or one of several salvage chemotherapy regimens, administered in 28-day cycles until treatment failure or other study endpoints.
Visits occur at the start of each 28-day treatment cycle; efficacy assessments occur on Day 1 of cycles 2, 3, 4, 5, 6, 7 and every other cycle thereafter
Duration - 1 week
Participants return to the study site for follow-up within 1 to 7 days after stopping treatment or before starting other anti-tumor therapy.
1 visit (in-person)
Duration - 30 days (±7 days)
Participants are monitored for safety and adverse events within approximately 30 days after the last dose or before starting other anti-tumor therapy.
1 visit (in-person)
Duration - Up to approximately 33 months
Participants without disease progression or relapse are advised to remain in the study for periodic monitoring every 8 weeks to assess event-free survival until disease progression, death, withdrawal, loss to follow-up, or study end.
Visits every 8 weeks
Duration - Up to approximately 33 months
Participants who have completed EFS follow-up due to disease progression or relapse receive ongoing survival monitoring every 8 weeks until death, withdrawal, loss to follow-up, or study end.
Visits every 8 weeks
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Lijuan Hu, Xudong Wei, Weili Zhao...
https://pubmed.ncbi.nlm.nih.gov/39892383/Hutchmed
Lead Sponsor